Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois
Cardio Diagnostics Announces It’s Exhibiting at the 2024 Onsite Employee Health Clinics Forum
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) had its price target raised by analysts at Benchmark Co. from $1.35 to $2.00. They now have a "speculative buy" rating on the stock.
Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services’ (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests